Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by PWIB123on Jan 04, 2023 11:57am
314 Views
Post# 35202857

Stocktwits continues to lose followers

Stocktwits continues to lose followersStocktwits followers are now at the lowest I've seen it in a very long time, around a dozen less than before the "pause" announcement.  When the value proposition was actually improving due to the steep decline in share price compared to a fairly stable fundamental profile, the number of followers interested in the stock was also in decline.  Paul's a sales guy.  I think of followers as potential customers who could buy your company's stock.  They don't have to.  They have many options.  What are you providing for them to convince them they should buy your stock instead of someone else's?  You should also think of followers as your sales team.  They are a free sales team willing and able to generate enormous leads that can result in millions of new investors.  If they believe, they will tell the world on your behalf.  All you have to do is guide them, and they'll do the work.  By the way, a lot of these followers are uneducated investors who will no doubt get your messaging entirely wrong.  My experience says it doesn't matter.  Followers arguing with each other over details usually results in more interested parties following the story.  Just start communicating!  Stocktwits and the followers on other discussion boards is a barometer to shareholder engagement.  
<< Previous
Bullboard Posts
Next >>